When we compared the same group of patients using our milk-diluent protocol (as recommended by the manufacturer) or a BSA-diluent protocol (as reported by Michael et al. [14]), we noticed that we were not able to detect differences in MIF serum levels of prostate cancer patients using the BSA-diluent protocol. The gene discussed is MIF; the disease is prostate carcinoma.